Interleukin-6 (IL-6) is a multifaceted cytokine that serves as a critical mediator in immune regulation, inflammation and tissue regeneration. Its activity is mediated through several signalling ...
Ultra running accelerates red blood cell ageing via inflammation and oxidation, mirroring blood bank storage damage.
Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
As baseline levels of IL-6 prior to hemodialysis AVF creation increase, so does the risk for AVF failure. Elevated levels of interleukin-6 (IL-6) prior to surgery to create an arteriovenous fistula ...
More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in ...
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company ...
Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...
A pioneering study presented today at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient ...
Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...
CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results